Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 3.36 mg (equivalent: granisetron, qty 3 mg) - injection, concentrated - excipient ingredients: water for injections; sodium chloride; nitrogen; citric acid monohydrate; sodium citrate dihydrate - granisetron injection is indicated in:,adults: - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy - for the prevention of nausea and vomiting induced by radiotherapy,children: - for the prevention of nausea and vomiting induced by cytotoxic chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride, quantity: 1.12 mg (equivalent: granisetron, qty 1 mg) - injection, concentrated - excipient ingredients: water for injections; sodium chloride; nitrogen; sodium citrate dihydrate; citric acid monohydrate - granisetron injection is indicated in:,adults: - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy - for the prevention of nausea and vomiting induced by radiotherapy,children: - for the prevention of nausea and vomiting induced by cytotoxic chemotherapy

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium hydroxide; sodium chloride; hydrochloric acid - adults:,kytril (tablets and injection) is indicated for use in adults for:,the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy. kytril (injection) is also indicated for use in the treatment of nausea and vomiting induced by cytotoxic chemotherapy; and prevention and treatment of post-operative nausea and vomiting.,paediatric:,kytril injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - granisetron hydrochloride - solution for injection - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - granisetron hydrochloride - solution for injection - 1mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 1 mg

United States - English - NLM (National Library of Medicine)

northstar rx llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

United States - English - NLM (National Library of Medicine)

bionpharma inc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.